![]() |
市場調查報告書
商品編碼
1410098
空間基因組學和轉錄組學市場:2023 年至 2028 年預測Spatial Genomics and Transcriptomics Market - Forecasts from 2023 to 2028 |
空間基因組學和轉錄組學市場預計在預測期內將以 17.38% 的複合年成長率成長。
空間基因組學和轉錄組學是指應用最尖端科技來幫助分析和視覺化基因表現模式。由於對精準醫學的需求不斷成長以及單細胞分析的進步,空間基因組學和轉錄組學市場正在顯著擴大。這些技術在許多領域具有巨大的潛力,因為它們同時提供了對組織內基因和遺傳物質的空間組織的洞察。這些技術將幫助癌症研究破解腫瘤微環境的複雜性和異質性,指導有針對性的治療方法和診斷的創建。
在藥物研發和開發中,對空間基因組學和轉錄組學市場的需求不斷成長。空間基因組學和轉錄組學擴大用於藥物研發發現和開發。這種需求的重點最近從研究轉向藥物研發發現和開發,尤其是對癌症和神經系統疾病等疾病的需求不斷增加。隨著第四代定序儀的出現以及空間基因組分析作為癌症診斷工具的潛力不斷增加,空間基因組學和轉錄組學市場預計將變得更加活躍。
來自學術機構的研究人員是影響基因組學和轉錄組學市場成長的關鍵因素。例如,費城兒童醫院等研究中心在學術和生物技術環境中擁有 GWAS 和基因座鑑定方面的專業知識。各種縱向和功能基因組中心正在建設中,以研究由遺傳性疾病引起的疾病型態,例如糖尿病、阿茲海默症。此外,基因組和轉錄組技術在該領域得到了更廣泛的應用,包括人類細胞圖譜。這些是影響基因組學和轉錄組市場佔有率佔有率成長的關鍵因素。
空間基因組研究經常在學術研究機構中使用,以提供對多種疾病的深入研究。例如,費城兒童醫院研究中心建立了空間和功能基因組學中心,利用基於 3D 基因組學的方法研究幾種流行疾病的遺傳基礎。大學研究人員可以透過空間基因組學和轉錄組學來探索基因表現動態的新領域。這種方法對於分析遺傳疾病的細胞型態狀態的學術研究人員很有價值,並已應用於人類細胞圖譜等研究計劃。
與基因組學領域相比,擴大採用轉錄組學進行單細胞轉錄組學分析,進一步推動了太空基因組學和轉錄組學市場的擴張。雷射捕獲晶粒切割技術(LCM)等自動化序列測定技術正在滿足生物材料核酸序列測定的需求,推動空間基因組學業務的擴張。此外,對組織異質性的理解的加深催生了最先進的測序資料資料以後使用。預計這一方面將在預期期間推動空間基因組學和轉錄組學市場的成長。
由於疾病病理學研究的策略性投資以及轉錄組學研究和開發的重要性日益增加,預計北美將出現強勁成長。例如,美國衛生研究院通用基金正在進行的單細胞分析計畫的重點是使用定序方法和基於螢光的方法來提高空間解析度。
隨著許多綜合醫院和其他相關組織實施基於基因組學的疾病預防,市場預計將隨著新技術的發展和產品的推出而擴大。例如,2022年3月,美國國立衛生研究院宣布已收集了來自不同物種的約10萬個全基因組序列。
多家綜合醫院和其他有興趣的機構引入基因組疾病預防,以及新的進展和產品的發布,預計將推動該行業的成長。例如,Illumina 和 Genetic Alliance 於 2021 年 11 月推出了一項耗資 1.2 億美元的全球宣傳活動,旨在增加公平性並改善受遺傳疾病影響的家庭的結果。此外,美國國立衛生研究院於 2022 年 3 月宣布,已從多個物種收集了約 10 萬個全基因組序列。這表明北美政府機構高度重視基因組學,預計這將在預測期內推動空間基因組學和轉錄組學市場的成長。
Visium 空間基因表現是一種下一代分子分析技術,可根據總 mRNA 對組織進行分類。此外,整個轉錄組將映射到 FFPE 或新鮮冷凍組織的型態背景上,以獲得對健康發育、疾病病理學和臨床轉化研究的新見解。 GeoMx 數位空間分析器 對於空間轉錄組和空間蛋白質組研究,GeoMx 數位空間分析器 (DSP) 僅透過一張幻燈片即可提供型態背景。 GeoMx DSP 是適應性最強、最可靠的空間生物學系統,旨在滿足從探索性研究到轉化性研究不斷變化的研究需求。
2023 年 2 月,Curio Bioscience 宣布商業發布 Curio Seeker,這是一種使用高解析度成像方法的全轉錄組空間作圖套件。 2022年10月,Oxford Nanopore Technologies與10x Genomics共同開發了用於單細胞和空間全長異構體定序的耗材。 2022 年 6 月,在奧蘭多舉行的 AGBT 大會上,10x Genomics 宣布了包括 Chromium、Visium 和 Xenium 在內的新產品。
The spatial genomics and transcriptomics market is estimated to grow at a CAGR of 17.38% during the forecast period.
Spatial genomics and transcriptomics are referred to as the application of cutting-edge technologies that help with the analysis of gene expression patterns and visualizations. The market for spatial genomics and transcriptomics is expanding significantly due to the growing need for precision medicine and the progress made in single-cell analysis. These technologies have great potential in a number of sectors since they provide insights into the spatial organisation of genes and genetic material within tissues at the same time. They aid in the deciphering of the complexity of tumour microenvironments and heterogeneity in cancer research, directing the creation of focused treatments and diagnostics.
Drug discovery and development is experiencing an increasing need for spatial genomics and transcriptomics markets. Drug discovery and development are seeing increasing applications for spatial genomics and transcriptomics. The focus of this demand has recently shifted from research to drug discovery and development, notably for diseases like cancer and neurological illnesses. The launch of the fourth generation of sequencing and the growing potential of spatial genomic analysis as a cancer diagnosis tool is expected to further fuel the spatial genomics and transcriptomics market.
Researchers from academic institutes are the major element influencing genomics and transcriptomics market growth. For instance, a research centre like Children's Hospital for Philadelphia has expertise in GWAS and locus identification in both academic and biotech environments. Various longitudinal and functional genomics centres have been built to investigate the morphology of diseases brought by genetic disorders, including diabetes, cancer, and Alzheimer's. Additionally, there are more extensive uses for genomic and transcriptomic technology in the field, including the Human Cell Atlas. These are the key factors influencing the growth of genomics and transcriptomics market share.
The spatial genomic studies are being used frequently in academic research facilities as they offer a thorough study of a wide range of illnesses. For instance, the Children's Hospital of Philadelphia's research centre has established a Centre of Spatial and Functional Genomics to investigate the genetic basis of several prevalent illnesses using 3D genomics-based methods. Researchers at universities can investigate novel regions of gene expression dynamics due to spatial genomics and transcriptomics. The approach is valuable for academic researchers who analyse the morphological status of cells for genetically derived disorders and find applications in research projects like the Human Cell Atlas.
The spatial genomics and transcriptomics market expansion is further fueled by the increased adoption of transcriptomics for single-cell transcriptomics analysis as compared to the genomics segment. The demand for nucleic acid sequencing of biological materials has been answered by automated sequencing techniques like the laser capture microdissection technique (LCM), which has propelled the expansion of the spatial genomics business. Additionally, a heightened understanding of tissue heterogeneity has sparked the creation of cutting-edge sequencing technology intended to archive genetic or spatial data for later use. It is predicted that during the anticipated period, this aspect will fuel spatial genomics and transcriptomics market growth.
North America is anticipated to grow significantly due to the strategic investments in disease pathology research and the increasing importance of transcriptomics R&D. For instance, the ongoing Single Cell Analysis Programme of the National Institutes of Health Common Fund focuses on sequencing methodologies and improving spatial resolution using fluorescence-based approaches.
Numerous general hospitals and other concerned organisations' implementation of genomics-based illness prevention is anticipated to aid the market's expansion along with new technological developments and product introductions. For instance, in March 2022, the National Institutes of Health declared that it had a collection of around 100,000 whole-genome sequencing from diverse species.
The introduction of preventative illness through genomics by several general hospitals and other concerned organisations is predicted to fuel the industry growth along with new advancements and product releases. For instance, Illumina and the Genetic Alliance established a USD 120 million worldwide campaign in November 2021 to boost fairness and improve outcomes for families impacted by genetic disorders. Furthermore, The National Institutes of Health also announced in March 2022 that it had a collection of approximately 100,000 whole-genome sequencing from a wide range of species. This suggests that North American government organisations place a high priority on genomics, which is anticipated to fuel the spatial genomics and transcriptomics market's growth throughout the projected period.